SK bioscience-flu vaccine SK bioscience to provide 5 mln doses of cell-based flu vaccine SKYCellfluBy Kim Boram ANDONG, South Korea, Aug. 23 (Yonhap) -- SK bioscience Co., a pharmaceutical affiliate under South Korea's SK Group, said Wednesday it will produce 5 million doses of its signature cell-based influenza vaccine SKYCellflu nationwide from next month for the coming winter season. It resumed the production two years after it had stopped manufacturing the prefilled syringe-typed vaccine due to the COVID-19 pandemic.

https://n.news.naver.com/mnews/article/001/0014147738?sid=104

#naver